Cholesterol reduction and death from noncoronary causes: evidence from randomised controlled trials

Abstract

An overview of randomised trials of cholesterol reduction (26 trials, 50,000 patients, net cholesterol reduction ˜10%) provides clear evidence of a reduction in the incidence of coronary heart disease (CHD) after just a few years of treatment. Overall, the observed reduction in CHD death (9%± 3) was only half as large as the reduction in non‐fatal myocardial infarction (19%±4), although both were statistically significant (2p <0.005). In these trials, 60% of all deaths were from CHD, and since treatment reduced these by about 9%, the expected reduction in total deaths was about 5–6%. This expected reduction falls within the 95% confidence interval of the observed effect of cholesterol reduction on total mortality in these trials. There were small excesses of deaths from cancer and deaths from trauma among patients allocated active treatment. However, in no single trial, nor in the trials collectively, were these increases individually statistically significant. Furthermore, the increases did not appear to be specific to any one agent nor were the increases consistent between trials of the same agent. These observations suggest that the small excesses of noncoronary deaths observed in the cholesterol reduction trials may have occurred by chance. Evidence from ongoing longer‐term studies of treatments producing larger cholesterol reductions will be useful in further delineating the effects, if any, of such treatments on non‐coronary mortality. Copyright © 1994, Wiley Blackwell. All rights reserved